News Breaks |
|
|
| February 1, 2013 |
| 07:05 EDT |  | MRK | Merck says now anticipates odanacatib filing in 2014
Merck reported it recently received and is reviewing safety and efficacy data from the pivotal Phase III trial of odanacatib, the company’s investigational medicine for osteoporosis. As previously indicated, the company has been conducting a blinded extension of the trial in approximately 8,200 women, which will provide additional safety and efficacy data. Merck now anticipates that it will file applications for approval of odanacatib in 2014 with additional data from the extension trial, rather than filing in the first half of 2013. The company continues to believe that odanacatib will have the potential to address unmet medical needs in patients with osteoporosis. |
|
|
News For MRK From The Last 14 Days Check below for free stories on MRK the last two weeks. |
|
|
| June 19, 2013 |
| 09:38 EDT |  | MRK | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL AMAT FDX MA C GOOG DISH AMRN MRK BIDU |
|
| June 18, 2013 |
| 16:00 EDT | | MRK | Options Update; June 18, 2013
 Subscribe for More Information |
|
| 08:37 EDT |  | MRK | Drug companies turn to microchips to test medicines, WSJ reports
Subscribe for More Information |
|
| June 17, 2013 |
| 08:36 EDT | | MRK | InSite Vision to join Merck, Pfizer patent suit against Mylan
InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. |
|
| June 14, 2013 |
| 17:15 EDT | | MRK | Merck cutting layer of R&D management, WSJ reports
Merck is planning to cut jobs and strip a level of senior management from its R&D unit, reports The Wall Street Journal. Reference Link |
|
| 13:21 EDT | | MRK | Merck to cut jobs, restructure R&D unit, Dow Jones reports
|
|
| June 12, 2013 |
| 16:02 EDT | | MRK | Options Update; June 12, 2013
Subscribe for More Information |
|
| 10:35 EDT |  | MRK | Merck management to meet with ISI Group
Subscribe for More Information |
|
| 08:04 EDT | | MRK | Merck says independent review of JANUVIA safety profile 'welcomed'
Subscribe for More Information |
|
| June 11, 2013 |
| 08:01 EDT | | MRK | Leerink's major pharma and biotech analysts hold a conference call
Subscribe for More Information |
| |
| 07:42 EDT | | MRK | Boston Biotech Conferences to host a conference
Subscribe for More Information |
|
| June 10, 2013 |
| 11:41 EDT | | MRK | Merck loss in Nasonex patent fight upheld on appeal
Merck Sharp & Dohme, formerly known as Schering, appealed a lower court ruling in favor of Apotex. Reference Link |
|
| June 6, 2013 |
| 16:01 EDT | | MRK | Options Update; June 6, 2013
CBOE Volatility Index VIX down 72c to 16.78. Option volume leaders: AAPL TSLA GOOG C MRK BAC according to Track Data. |
|
| June 5, 2013 |
| 06:09 EDT | | MRK | Merck implied volatility at upper end of index mean range
|
|
|
|
|
|
